Form 4: iBio Director Arkowitz Granted 13,500 Stock Options

iBio Director David Arkowitz received a grant of 13,500 stock options with an exercise price of $1, vesting monthly over 12 months.

Summary

• David Arkowitz, a Director of iBio, Inc. (IBIO), was granted 13,500 stock options.
• The transaction date for this grant was November 20, 2025.
• Each option has an exercise price of $1.
• The options vest pro rata on a monthly basis over a twelve-month period, starting from the grant date.
• The options have an expiration date of November 19, 2035.
• Following this transaction, David Arkowitz beneficially owns 13,500 derivative securities (stock options).

Sentiment

Score: 6

Explanation: Neutral to slightly positive. The grant of options is a routine compensation event that aligns director interests with shareholders, but it does not provide new operational or financial performance insights.

Positives

• The grant of stock options aligns the director's interests with those of shareholders, incentivizing long-term company performance.
• The vesting schedule encourages continued service and commitment from the director over the next year.

Negatives

• No explicit negatives are detailed in this routine insider transaction filing.

Risks

• No specific risks are detailed in this Form 4 filing.

Future Outlook

The vesting schedule indicates that the director's equity stake will gradually increase over the next twelve months, contingent on continued service.

Industry Context

This is a standard compensation practice for directors in publicly traded companies across various industries, aiming to align leadership incentives with shareholder value.

Comparison to Industry Standards

• The grant of stock options to directors is a common practice in the biotechnology and pharmaceutical sectors, similar to companies like Moderna or Pfizer, to retain talent and align interests.
• The vesting period of 12 months is relatively short compared to some executive grants which might span 3-4 years, but it is within the typical range for director-level equity compensation.
• The exercise price of $1, if it represents the fair market value on the grant date, is standard for at-the-money options.

Stakeholder Impact

• Shareholders: The grant of options aims to align the director's long-term interests with shareholder value creation.

Next Steps

• The stock options will vest pro rata on a monthly basis over the next twelve months.
• The director may choose to exercise the vested options at any point before their expiration date of November 19, 2035.

Key Dates

Keywords

iBio, IBIO, stock options, insider transaction, Form 4, director compensation, equity grant, David Arkowitz